Abstract:Co-delivery of chemotherapeutic drug and small interfering RNA (siRNA) within a single nanovehicle has emerged as a promising combination therapy approach to treating cancers because of their synergistic effect. Nanocarrier delivery systems with low cytotoxicity and high efficiency are needed for such a purpose. In this study, a novel folate-conjugated PEGylated cationic triblock copolymer, poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine) (PAH-b-PDMAPMA-b-PAH), was synthesized and evaluated as a stimuli-sensitive vehicle for the targeted co-delivery of doxorubicin (DOX) and Bcl-2 siRNA into breast cancer MCF-7 cells. The synthetic process of the PEGylated triblock copolymer involved sequential reversible addition-fragmentation chain transfer polymerization, PEGylation and removal of tert-butoxy carbamate protecting groups. Folate-conjugated and/or -unconjugated poly(ethylene glycol) segments were grafted onto PAH-b-PDMAPMA-b-PAH via a reduction-sensitive disulfide linkage. The synthetic polymers were characterized by 1H NMR and gel permeation chromatography. The PEGylated triblock copolymer could chemically conjugate DOX onto PAH blocks via pH-responsive hydrazone bonds and simultaneously complex negatively charged Bcl-2 siRNA with cationic PDMAPMA blocks through electrostatic interactions at N/P ratios≥32:1 to form multifunctional nanomicelleplexes. The nanomicelleplexes exhibited spherical shape, possessed a positively charged surface with a zeta potential of +22.5mV and had a desirable and uniform particle size of 187nm. In vitro release studies revealed that the nanomicelleplexes could release DOX and Bcl-2 siRNA in a reduction and pH dual-sensitive manner and the payload release was significantly enhanced in a reductive acidic environment mimicking the endosomes/lysosomes of cancer cells compared to under physiology conditions. Furthermore, the release of both DOX and siRNA was found to follow Higuchi kinetic model. Confocal laser scanning microscopy, flow cytometry and MTT analyses confirmed that, compared with folate-undecorated nanomicelleplexes, folate-decorated nanomicelleplexes could more effectively co-deliver DOX and Bcl-2 siRNA into MCF-7 cells and showed a stronger cell-killing effect. The pristine PEGylated triblock copolymer exhibited good cytocompatibility. Moreover, co-delivery of DOX and Bcl-2 siRNA achieved a significant synergistic antitumor efficacy. These findings suggested that the folate-decorated PEGylated cationic triblock copolymer might be a promising vehicle for targeted intracellular co-delivery of DOX and siRNA in MCF-7 cells, representing a potential clinical combination therapy for breast cancer treatment.

Exosomal fragment enclosed polyamine-salt nano-complex for co-delivery of docetaxel and mir-34a exhibits higher cytotoxicity and apoptosis in breast cancer cells

Cytosolic Co-Delivery of Mirna-34A and Docetaxel with Core-Shell Nanocarriers Via Caveolae-Mediated Pathway for the Treatment of Metastatic Breast Cancer.

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects.

Macrophage derived Exosomal Docetaxel (Exo-DTX) for pro-metastasis suppression: QbD driven formulation development, validation, in vitro and pharmacokinetic investigation

Ratiometric Co-Delivery of Doxorubicin and Docetaxel by Covalently Conjugating with Mpeg-Poly(β-malic Acid) for Enhanced Synergistic Breast Tumor Therapy

Combination of Using Prodrug-Modified Cationic Liposome Nanocomplexes and a Potentiating Strategy Via Targeted Co-Delivery of Gemcitabine and Docetaxel for CD44-overexpressed Triple Negative Breast Cancer Therapy

Ratiometric co-delivery of doxorubicin and paclitaxel prodrug by remote-loading liposomes for the treatment of triple-negative breast cancer

Synergistic Breast Tumor Cell Killing Achieved by Intracellular Co-Delivery of Doxorubicin and Disulfiram Via Core-Shell-corona Nanoparticles

Enhanced docetaxel therapeutic effect using dual targeted SRL-2 and TA1 aptamer conjugated micelles in inhibition Balb/c mice breast cancer model

Codelivery of Doxorubicin/PI3K Inhibitor Nanomicelle Linked with Phenylboronic Acid for Enhanced Cytotoxicity to Pancreatic Cancer

Co-Delivery of Doxorubicin and Sirna with Reduction and Ph Dually Sensitive Nanocarrier for Synergistic Cancer Therapy

Co-Delivery of Docetaxel and Salinomycin to Target Both Breast Cancer Cells and Stem Cells by PLGA/TPGS Nanoparticles

Folate-decorated PEGylated Triblock Copolymer As a Ph/reduction Dual-Responsive Nanovehicle for Targeted Intracellular Co-Delivery of Doxorubicin and Bcl-2 Sirna.

Co-delivery of DOX and PDTC by Ph-Sensitive Nanoparticles to Overcome Multidrug Resistance in Breast Cancer.

Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer.

Efficient Co-delivery of Doxorubicin and Methotrexate by Ph-Sensitive Dual-Functional Nanomicelles for Enhanced Synergistic Antitumor Efficacy

Co-delivery of siRNA and docetaxel by hyaluronic acid modified redox-sensitive disulfide-crosslinked nanoparticles

Dendrimer-based Multilayer Nanocarrier for Potential Synergistic Paclitaxel–doxorubicin Combination Drug Delivery

Co-delivery of doxorubicin and curcumin by polymeric micelles for improving antitumor efficacy on breast carcinoma

Self-Delivering Prodrug-Nanoassemblies Fabricated by Disulfide Bond Bridged Oleate Prodrug of Docetaxel for Breast Cancer Therapy